A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1)
暂无分享,去创建一个
Y. Kurihara | H. Miyoshi | K. Oba | T. Atsumi | H. Tsutsui | T. Furumoto | A. Inoue | H. Nomoto | S. Aoki | N. Manda
[1] I. Shimomura,et al. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE) , 2016, Diabetes Care.
[2] Y. Kurihara,et al. A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2) , 2015, PloS one.
[3] M. Pencina,et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.
[4] Deepak L. Bhatt,et al. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial , 2014, Diabetes Care.
[5] S. Rani,et al. Apoptosis of beta cells in diabetes mellitus. , 2014, DNA and cell biology.
[6] Yining Yang,et al. Adiponectin Abates Atherosclerosis by Reducing Oxidative Stress , 2014, Medical science monitor : international medical journal of experimental and clinical research.
[7] T. Funahashi,et al. A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus- a randomized controlled trial START-J study , 2014, Cardiovascular Diabetology.
[8] Yan Wu,et al. Angiotensin II Receptor Blockers Improve Peripheral Endothelial Function: A Meta-Analysis of Randomized Controlled Trials , 2014, PloS one.
[9] L. Bardram,et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. , 2014, Endocrinology.
[10] T. Okamoto,et al. Acute effect of brisk walking with graduated compression stockings on vascular endothelial function and oxidative stress , 2013, Clinical physiology and functional imaging.
[11] F. Pattou,et al. The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization. , 2013, The Journal of clinical endocrinology and metabolism.
[12] Harumi Uto-Kondo,et al. Dipeptidyl Peptidase‐4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow‐Mediated Vasodilatation in Type 2 Diabetic Patients , 2013, Journal of the American Heart Association.
[13] S. Hahn,et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis , 2013, Diabetologia.
[14] Ryuzo Kawamori,et al. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. , 2013, Endocrinology.
[15] K. Mizuno,et al. The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes , 2012, Journal of Korean medical science.
[16] H. Takagi,et al. Low-density lipoprotein-independent improvement of flow-mediated dilatation with atorvastatin: a meta-analysis and meta-regression of randomized controlled trials. , 2012, International journal of cardiology.
[17] S. Yamagishi,et al. Sitagliptin Augments Protective Effects of GLP-1 against Advanced Glycation End Product Receptor Axis in Endothelial Cells , 2011, Hormone and Metabolic Research.
[18] M. Netea,et al. Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes , 2011, Diabetes Care.
[19] A. Dear,et al. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model , 2011, Diabetes & vascular disease research.
[20] A. Dear,et al. Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen [corrected] activator inhibitor-1 expression. , 2010, The Journal of endocrinology.
[21] R. D. de Boer,et al. Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species–Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[22] The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2010, The Lancet.
[23] R. Kawamori,et al. Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4 , 2010, Diabetes.
[24] S. Hollenberg,et al. Bench-to-bedside review: Nitric oxide in critical illness – update 2008 , 2009, Critical care.
[25] K. Naka,et al. Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes. , 2009, Atherosclerosis.
[26] D. Doudet,et al. Inhibition of Dipeptidyl Peptidase IV With Sitagliptin (MK0431) Prolongs Islet Graft Survival in Streptozotocin-Induced Diabetic Mice , 2008, Diabetes.
[27] T. Rabelink,et al. Endothelial function and dysfunction: testing and clinical relevance. , 2007, Circulation.
[28] Yue Feng,et al. Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes , 2006, Diabetes.
[29] T. Wascher,et al. Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance , 2005, European journal of clinical investigation.
[30] S. Kazui,et al. Mortality and Cause of Death after Hospital Discharge in 10,981 Patients with Ischemic Stroke and Transient Ischemic Attack , 2005, Cerebrovascular Diseases.
[31] J. Holst,et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. , 2004, American journal of physiology. Endocrinology and metabolism.
[32] L. Bouter,et al. Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not; The Hoorn Study. , 2004, Atherosclerosis.
[33] B. Sobel,et al. Maladaptive arterial remodeling with systemic hypertension associated with increased concentrations in blood of plasminogen activator inhibitor type-1 (PAI-1). , 2004, The American journal of cardiology.
[34] B. Lewis,et al. Brachial artery endothelial function in residents and fellows working night shifts. , 2004, The American journal of cardiology.
[35] E. Benjamin,et al. Clinical Correlates and Heritability of Flow-Mediated Dilation in the Community: The Framingham Heart Study , 2004, Circulation.
[36] F. Ruschitzka,et al. Mental Stress Induces Prolonged Endothelial Dysfunction via Endothelin-A Receptors , 2002, Circulation.
[37] Peter Libby,et al. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.
[38] E. Benjamin,et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. , 2002, Journal of the American College of Cardiology.
[39] J. Callés-Escandon,et al. Diabetes and endothelial dysfunction: a clinical perspective. , 2001, Endocrine reviews.
[40] A. Zeiher,et al. Insulin-mediated stimulation of protein kinase Akt: A potent survival signaling cascade for endothelial cells. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[41] A. Nicolaides,et al. A simple test to monitor oxidative stress. , 1999, International angiology : a journal of the International Union of Angiology.
[42] A. Henderson. Endothelial dysfunction: a reversible clinical measure of atherogenic susceptibility and cardiovascular inefficiency. , 1997, International journal of cardiology.
[43] P. Vallance,et al. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. , 1997, Circulation.
[44] J. Polak,et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. , 1993, Circulation.
[45] S. Marklund,et al. CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse. , 1981, The Biochemical journal.
[46] T. Sawada,et al. Comparison of effects of α-Glucosidase inhibitors and glinide drugs on endothelial dysfunction in diabetic patients with coronary artery disease. , 2014, Circulation journal : official journal of the Japanese Circulation Society.
[47] K. Kario,et al. A multicenter study design to assess the clinical usefulness of semi-automatic measurement of flow-mediated vasodilatation of the brachial artery. , 2012, International heart journal.
[48] H. Kumagai,et al. Seasonal variation of endothelium-dependent flow-mediated vasodilation measured in the same subjects. , 2012, American journal of cardiovascular disease.
[49] M. Hollenberg,et al. Review Bench-to-bedside review: Nitric oxide in critical illness - update , 2009 .
[50] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .